| scholarly article | Q13442814 |
| P50 | author | Wenjie Tan | Q90270090 |
| P2093 | author name string | Jianfang Zhou | |
| Kun Qin | |||
| Yongliang Lou | |||
| Yingzhu Chen | |||
| Hao Jia | |||
| Yao Deng | |||
| Shuai Lu | |||
| Wenling Wang | |||
| Baoying Huang | |||
| Yueyang Yu | |||
| Jiaming Lan | |||
| P2860 | cites work | Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 |
| Receptor-binding domain-based subunit vaccines against MERS-CoV | Q26851979 | ||
| Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor | Q27670427 | ||
| Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 | Q27678981 | ||
| Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus | Q27679307 | ||
| Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers | Q27683553 | ||
| Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits | Q28602816 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? | Q30223960 | ||
| Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. | Q30359335 | ||
| Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. | Q30362113 | ||
| A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. | Q30379384 | ||
| Pre-fusion structure of a human coronavirus spike protein. | Q30385177 | ||
| Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development | Q30432706 | ||
| Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia | Q33569544 | ||
| Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | Q33627189 | ||
| Hospital outbreak of Middle East respiratory syndrome coronavirus | Q33642332 | ||
| A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. | Q33743790 | ||
| Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus | Q34120263 | ||
| Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design | Q34324907 | ||
| Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein | Q34408840 | ||
| Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease | Q34468689 | ||
| The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies | Q34653419 | ||
| A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines | Q35063993 | ||
| Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein | Q35159147 | ||
| Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. | Q35163604 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus | Q35887626 | ||
| Evaluation of candidate vaccine approaches for MERS-CoV. | Q35917397 | ||
| 2015 MERS outbreak in Korea: hospital-to-hospital transmission. | Q35942360 | ||
| Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | Q35989939 | ||
| Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge | Q36252666 | ||
| Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans | Q36432023 | ||
| Identification and Comparison of Receptor Binding Characteristics of the Spike Protein of Two Porcine Epidemic Diarrhea Virus Strains | Q36735622 | ||
| Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus | Q36825522 | ||
| The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns". | Q38123917 | ||
| MERS-CoV vaccine candidates in development: The current landscape | Q38809401 | ||
| Middle East respiratory syndrome: current status and future prospects for vaccine development | Q38959242 | ||
| Transmissible gastroenteritis coronavirus, but not the related porcine respiratory coronavirus, has a sialic acid (N-glycolylneuraminic acid) binding activity. | Q39875698 | ||
| Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding | Q40397876 | ||
| Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies | Q40437929 | ||
| Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea | Q40689328 | ||
| Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea | Q40867001 | ||
| Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates | Q41477234 | ||
| Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. | Q42152380 | ||
| Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation | Q42236132 | ||
| Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. | Q42269949 | ||
| Middle East respiratory syndrome coronavirus infections in health care workers | Q45723498 | ||
| A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. | Q46374737 | ||
| P433 | issue | 5 | |
| P921 | main subject | monoclonal antibody | Q422248 |
| Middle East respiratory syndrome coronavirus | Q4902157 | ||
| spike glycoprotein | Q88660566 | ||
| P304 | page(s) | e37 | |
| P577 | publication date | 2017-05-24 | |
| P1433 | published in | Emerging Microbes & Infections | Q27724513 |
| P1476 | title | A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein | |
| P478 | volume | 6 |
| Q97519840 | A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS |
| Q93369404 | A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry |
| Q89470675 | An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies |
| Q84315455 | Antibodies and vaccines against Middle East respiratory syndrome coronavirus |
| Q59136770 | Broad neutralizing activity of a human monoclonal antibody against H7N9 strains from 2013 to 2017 |
| Q95602418 | Coronaviruses pandemics: Can neutralizing antibodies help? |
| Q56971688 | Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models |
| Q47607374 | Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges |
| Q63246138 | Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies |
| Q100464664 | Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity |
| Q54241763 | Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. |
| Q95298068 | From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development |
| Q84315478 | Middle East Respiratory Syndrome Coronavirus in Dromedaries in Ethiopia Is Antigenically Different From the Middle East Isolate EMC |
| Q98157481 | Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 |
| Q60925703 | Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection |
| Q89568621 | Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein |
| Q91809315 | Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein |
| Q92073421 | Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus |
Search more.